The agreement encompasses development and commercial milestones for the products, which could amount to up to $180m.

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Detecting tryptophan and other metabolites can be done using various techniques. Researchers created a new UHPLC–MS/MS-based ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

Tevimbra is currently approved in the EU as a treatment for gastric cancer, esophageal squamous cell cancer and small cell ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global ...

Successfully completing an EMA eCTD 4.0 test submission, Ennov gives customers early readiness, lower risk, and smoother compliance. This gives our customers a clear advantage. When the next pilot ...

The relentless hunger and associated behaviours significantly impact the quality of life for those with Prader-Willi syndrome ...